Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00049985
Status:
COMPLETED
Last Update Posted:
2009-08-07
First Post:
2002-11-18
Brief Title:
Heart Failure and Anemia
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Double-blind Randomized Placebo-controlled Multicenter Study to Assess the Impact of Subcutaneous SC Darbepoetin Alfa Treatment on Exercise Tolerance in Subjects With Symptomatic Heart Failure CHF and Anemia
Status:
COMPLETED
Status Verified Date:
2009-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether increasing hemoglobin concentration in patients with heart failure and anemia will improve the patients functional status including exercise tolerance and New York Heart Association NYHA classification
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None